|
Market Closed -
OTC Markets
17:57:58 03/06/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.1052 USD | -2.09% |
|
+5.04% | -87.61% |
| 08-14 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 08-13 | Casi Pharmaceuticals, Inc. Announces Management Changes | CI |
| Market Cap | 2.67M 2.4M 2.2M 2M 3.73M 254M 3.8M 26.28M 10.55M 134M 10.04M 9.83M 421M | P/E 2024 |
-1.11x | P/E 2025 | -0.33x |
|---|---|---|---|---|---|
| Enterprise Value | 24.53M 21.97M 20.21M 18.31M 34.22M 2.33B 34.87M 241M 96.73M 1.23B 92.05M 90.1M 3.86B | EV / Sales 2024 |
1.75x | EV / Sales 2025 | 1.9x |
| Free-Float |
53.46% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -2.09% | ||
| 1 week | +5.04% | ||
| Current month | -8.20% | ||
| 1 month | -8.20% | ||
| 3 months | -18.25% | ||
| 6 months | -29.80% | ||
| Current year | -87.61% |
| 1 week | 0.1 |  | 0.13 |
| 1 month | 0.1 | | 0.13 |
| Current year | 0.05 | | 1.2 |
| 1 year | 0.05 | | 1.48 |
| 3 years | 0.05 | | 8.48 |
| 5 years | 0.05 | | 11.7 |
| 10 years | 0.05 | | 88.92 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Cory
CEO | Chief Executive Officer | 62 | 21/07/2025 |
Kun Qian
DFI | Director of Finance/CFO | 44 | 16/05/2025 |
Chun Hua Wang
COO | Chief Operating Officer | 54 | 01/01/2017 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Wu
BRD | Director/Board Member | 62 | 01/04/2013 |
Zhen Bo Su
BRD | Director/Board Member | 50 | 21/03/2023 |
Thomas Folinsbee
BRD | Director/Board Member | 59 | 21/03/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 3/18/26 A | Emerging Technology Partners LLC
| Other | Company | 1,097,341 | 7.0830% | |
| 3/18/26 A | Panacea Venture
| Other | Company | 4,529,956 | 29.2393% | |
| 3/18/26 A | Other | Chief Financial Officer | 75,000 | 0.4841% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.09% | +5.04% | -92.26% | -97.08% | 2.67M | |
| +3.19% | +11.31% | +67.86% | +150.58% | 1,263B | |
| -0.73% | +3.56% | +44.51% | +85.81% | 658B | |
| +1.41% | +3.24% | +29.22% | +107.83% | 521B | |
| +0.42% | +3.20% | +54.15% | +67.18% | 391B | |
| +2.18% | +2.93% | +73.30% | +45.62% | 369B | |
| +1.12% | +4.52% | +35.30% | +58.08% | 307B | |
| +6.96% | +8.86% | +11.27% | +36.62% | 290B | |
| +1.15% | +6.09% | +59.59% | +77.06% | 252B | |
| +3.06% | +9.38% | +44.11% | +119.47% | 212B | |
| Average | +1.35% | +5.31% | +32.70% | +65.12% | 426.19B | |
| Weighted average by Cap. | +1.19% | +6.60% | +50.88% | +98.31% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 28.54M 25.56M 23.51M 21.3M 39.82M 2.71B 40.56M 280M 113M 1.43B 107M 105M 4.49B | 20.71M 18.55M 17.06M 15.46M 28.9M 1.97B 29.44M 203M 81.68M 1.03B 77.73M 76.08M 3.26B |
| Net income | -39.26M -35.16M -32.34M -29.3M -54.78M -3.73B -55.8M -386M -155M -1.96B -147M -144M -6.18B | -48.06M -43.04M -39.59M -35.87M -67.05M -4.56B -68.31M -472M -190M -2.4B -180M -177M -7.57B |
| Net Debt | 6.05M 5.42M 4.98M 4.52M 8.44M 574M 8.6M 59.44M 23.86M 302M 22.71M 22.22M 953M | 21.85M 19.57M 18M 16.31M 30.49M 2.08B 31.06M 215M 86.19M 1.09B 82.02M 80.27M 3.44B |
Employees
214
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | $0.1301 | +14.18% | 258 |
| 29/10/26 | $0.1140 | +13.96% | 11,522 |
| 27/10/26 | $0.1000 | -.--% | 252 |
| 26/10/26 | $0.1000 | -0.25% | 640 |
| 23/10/26 | $0.1003 | +0.15% | 4,142 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CASIF Stock
Select your edition
All financial news and data tailored to specific country editions
